IGF-methotrexate conjugate - IGF Oncology

Drug Profile

IGF-methotrexate conjugate - IGF Oncology

Alternative Names: 765-IGF-MTX; IGF-methotrexate conjugate; IGF/MTX

Latest Information Update: 08 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator IGF Oncology
  • Developer IGF Oncology; University of Chicago
  • Class Antineoplastics; Benzamides; Drug conjugates; Glutamates; Growth factors; Peptides; Pterins; Small molecules; Somatomedins
  • Mechanism of Action Immunosuppressants; Tetrahydrofolate dehydrogenase inhibitors; Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 08 Jun 2017 IGF Oncology plans a phase I/II trial for Myelodysplastic syndrome and Myeloid leukaemia (Late-stage disease, Second-line therapy or greater) in USA (NCT03175978)
  • 15 Dec 2016 Biomarkers information updated
  • 30 Sep 2016 University of Illinois at Chicago and IGF Oncology completes a phase I trial in Solid tumours (Second-line therapy or greater, Late-stage disease) in USA (NCT02045368)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top